Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q2 2023 vs. Q1 2023
How the institutions holding Alvotech changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 17 | 17 | 0 |
| Shares | 19.0M | 17.6M | −1.40M (−7.4%) |
| Value | $244.6M | $133.5M | −$111.1M (−45.4%) |
New holders (3)
Institutions that held Alvotech at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| National Asset Management, Inc. | 25,000 | $193.5K | 0.00% |
| HRT Financial LP | 16,855 | $130.0K | 0.00% |
| Royal Bank of Canada | 381 | $3.00K | 0.00% |
Sold out (3)
Institutions that held Alvotech at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Invesco Ltd. | 146,350 | $1.89M |
| UBS Group AG | 2,283 | $29.5K |
| Morgan Stanley | 1,193 | $15.4K |